Parkinson's Disease and Related Disorders

Oleh Hornykiewicz.- Melvin Yahr (19172004). An appreciation.- Melvin D. Yahr, 19172004. A personal recollection.- Melvin D. Yahr, 19172004. A personal recollection.- Pathology.- The discovery of dopamine deficiency in the parkinsonian brain.- Synchronizing activity of basal ganglia and pathophysiology of Parkinsons disease.- Basal ganglia discharge abnormalities in Parkinsons disease.- Bad oscillations in Parkinsons disease.- Cortical muscle coupling in Parkinsons disease (PD) bradykinesia.- GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons.- The engrailed transcription factors and the mesencephalic dopaminergic neurons.- The role of Pitx3 in survival of midbrain dopaminergic neurons.- Genetic analysis of dopaminergic system development in zebrafish.- Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinsons disease.- The nigrostriatal DA pathway and Parkinsons disease.- Relationship between axonal collateralization and neuronal degeneration in basal ganglia.- Pathology associated with sporadic Parkinsons disease where does it end?.- Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinsons disease.- A short overview on the role of ?-synuclein and proteasome in experimental models of Parkinsons disease.- The role of protein aggregates in neuronal pathology: guilty, innocent, or just trying to help?.- Iron and neuromelanin.- New face of neuromelanin.- The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells.- Potential sources of increased iron in the substantia nigra of parkinsonian patients.- Iron and Friedreichataxia.- Genetics.- Nongenetic causes of Parkinsons disease.- Is atypical parkinsonism in the Caribbean caused by the consumption of Annonacae?.- CYP450, genetics and Parkinsons disease: gene environment interactions hold the key.- Unique cytochromes P450 in human brain: implication in disease pathogenesis.- Cytochrome P450 and Parkinsons disease: protective role of neuronal CYP 2E1 from MPTP toxicity.- Nicotine induces brain CYP enzymes: relevance to Parkinsons disease.- Genetic causes of Parkinsons disease: extending the pathway.- Progress in familial Parkinsons disease.- Molecular mechanisms of nigral neurodegeneration in Park2 and regulation of parkin protein by other proteins.- Parkin and defective ubiquitination in Parkinsons disease.- PINK-1 and DJ-1 new genes for autosomal recessive Parkinsons disease.- Clinical and pathologic features of families with LRRK2-associated Parkinsons disease.- Molecular genetic findings in LRRK2 American, Canadian and German families.- Imaging.- Genetic and DAT imaging studies of familial parkinsonism in a Taiwanese cohort.- Neuroimaging in Parkinsons disease.- Transcranial sonography in the early and differential diagnosis of Parkinsons disease.- Models.- How to judge animal models of Parkinsons disease in terms of neuroprotection.- Limitations of cellular models in Parkinsons disease research.- The Rotenone model of Parkinsonism the five years inspection.- Controversies on new animal models of Parkinsons disease Pro and Con: the rotenone model of Parkinsons disease (PD).- Proposed animal model of severe Parkinsons disease: neonatal 6-hydroxydopamine lesion of dopaminergic innervation of striatum.- ?-Synuclein overexpression model.- Kynurenines, Parkinsons disease andother neurodegenerative disorders: preclinical and clinical studies.- Clinical approaches.- Whats new? Clinical progression and staging of Parkinsons disease.- Parkinsons disease: premotor clinico-pathological correlations.- Detection of preclinical Parkinsons disease along the olfactory trac(t).- The clinical approach to gait disturbances in Parkinsons disease; maintaining independent mobili